Humana falls 3.0% as healthcare sector slides, joint venture noted

What happened

Humana (HUM) fell 3.0% to close at $420.38 on October 13, 2026, as the healthcare sector weakened and the stock moved with its peers. The stock opened 1.3% above the previous close and trading volume was 1.2 times its 20-day average. The S&P 500 was unchanged on the day while the healthcare sector median fell 2.5%, leaving the stock 0.5 percentage points worse than the sector median.

How big was the move

The day's change was 1.2 times a typical daily move for this stock, consistent with a sector-wide move. Over the last five sessions the stock rose 4.0% while the S&P 500 fell 0.2% over the same span. Market sensitivity is moderate, with a beta of 1.02, meaning the stock tends to move about as much as the market.

The technical picture

The stock traded above its near-term averages, at 6.9% above its 20-day moving average and 7.7% above its 50-day moving average, and it remained 40.8% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 111 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) was 60, in a neutral range, and the share price sat 7.9% below the 52-week high.

Humana has risen 3.3% over one month and 3.1% over three months, and is up 50.0% over one year, outperforming the S&P 500 by 30.9 percentage points. Volatility measured 40% annualized over 60 days, higher than 60% of its own readings over five years, suggesting price swings have been larger than typical for the company.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $145.68 billion, which grew 18.3% from a year earlier. Diluted earnings per share were $10.56, with earnings per share growth having fallen 19.0% from a year earlier. Gross margin was 13.7% (a year earlier: 15.0%) and operating margin was 1.4% (a year earlier: 1.7%). Free-cash-flow margin was 0.3% and return on invested capital was 4.5%. The balance sheet showed net debt of 2.4 times EBITDA and share count over one year increased by 0.1%.

Valuation measures were elevated. The stock traded at 39.8 times trailing earnings, the highest reading of the past five years (five-year median: 20.5 times earnings), and at 45.9 times expected forward earnings. Free-cash-flow yield was 0.9%. PromtFinance scores rank the stock highly for Momentum at 94 (Exceptional) and positively on Value at 72 (Positive), while Quality is 28 (Very weak) and Revisions are 32 (Weak). Those contrasts—strong momentum alongside weak quality metrics and thin cash flow—underline a tradeoff between price action and underlying profitability.

Earnings and analyst expectations

Humana last reported on July 29, 2026, with earnings per share of $7.61 against $7.27 expected, 4.7% above estimates. The company has reported ten consecutive quarters beating estimates, with an average surprise over the last four reports of 4.2% above estimates, and a typical two-day reaction after recent reports was that the stock rose 0.5%.

The next report is scheduled for November 6, 2026, when Humana will release third-quarter 2026 financial results and host a live question-and-answer session. Analysts show a consensus price target of $460.74, 9.6% above the closing price, based on 44 analysts with a consensus rating of Hold; 43% of analysts rate the stock Buy. Given the stretched valuation and modest historical post-earnings reactions, investors may focus on revenue trends and any guidance the company provides on margins and cash flow.

What to watch

• November 6, 2026: third-quarter 2026 financial results, prepared management remarks at 6:00 a.m. Eastern and a live question-and-answer session at 8:00 a.m. Eastern (reported by Business Wire).
• Recent corporate transaction: a joint venture with funds and accounts managed by HPS Investment Partners, part of BlackRock, to take responsibility for nearly 150 senior primary care clinics operated under the CenterWell brand (reported by Business Wire).
• Shareholder notice circulated by a law firm regarding potential breaches of fiduciary duty by Humana insiders, offered on a contingent-fee basis (reported by PRNewsWire).
• Technical proximity to the 52-week high: stock is 7.9% below the 52-week high and 6.9% above its 20-day moving average.
• Valuation and cash flow metrics: 39.8 times trailing earnings and a free-cash-flow yield of 0.9%.